Association of Chronic Condition Special Needs Plan With Hospitalization and Mortality Among Patients With End-Stage Kidney Disease

Becker, Bryan N.; Luo, Jiacong; Gray, Kathryn S.; Colson, Carey; Cohen, David S.; McMurray, Stephen; Gregory, Bryan; Lohmeyer, Nathan; Brunelli, Steven M.

doi:10.1001/jamanetworkopen.2020.23663

Cited by 4 publications

(4 citation statements)

References 7 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies regarding utilisation of healthcare resources for CKD mostly focused on end-stage kidney disease (ESKD). [22][23][24] The US Renal Data System 2019 Annual Data Report showed that the costs for both CKD and ESKD were in excess of $120 billion in 2017, and the latter accounted for more than 7.2% of the total Medicare expenditure. 25 Our study revealed that CKD was associated with a 6.8% increase in costs, which was higher than that of hypertension, diabetes and COPD.…”

Section: Discussionmentioning

confidence: 99%

Healthcare resource utilisation for chronic kidney disease and other major non-communicable chronic diseases in China: a cross-sectional study

Yang

Long

Shi³

et al. 2022

BMJ Open

View full text Add to dashboard Cite

ObjectiveTo evaluate the healthcare resource utilisation for chronic kidney disease (CKD) and other major non-communicable chronic diseases (NCDs) in China.DesignA cross-sectional study.SettingA national inpatient database of tertiary hospitals in China.ParticipantsThe study included a total of 19.5 million hospitalisations of adult patients from July 2013 to June 2014. Information on CKD and other major NCDs, including coronary heart disease (CHD), stroke, hypertension, diabetes, chronic obstructive pulmonary disease (COPD) and cancer, was extracted from the unified discharge summary form.Outcome measuresCost, length of hospital stay and in-hospital mortality.ResultsThe percentages of hospitalisations with CKD, CHD, stroke, hypertension, diabetes, COPD and cancer were 4.5%, 9.2%, 8.2%, 18.8%, 7.9%, 2.3% and 19.4%, respectively. For each major NCD, the presence of CKD was independently associated with longer hospital stay, with increased percentages ranging from 7.69% (95% CI 7.11% to 8.28%) for stroke to 21.60% (95% CI 21.09% to 22.10%) for CHD. Hospital mortality for other NCDs was also higher in the presence of CKD, with fully adjusted relative risk ranging from 1.91 (95% CI 1.82 to 1.99) for stroke to 2.65 (95% CI 2.55 to 2.75) for cancer. Compared with other NCDs, CKD was associated with the longest hospital stay (22.1% increase) and resulted in the second highest in-hospital mortality, only lower than that of cancer (relative risk, 2.23 vs 2.87, respectively).ConclusionsThe presence of diagnosed CKD alongside each major NCD was associated with an additional burden on the healthcare system. Healthcare resource utilisation and prognosis of CKD were comparable with those of other major NCDs, which highlights the importance of CKD as a major public health burden.

show abstract

Section: Discussionmentioning

confidence: 99%

Healthcare resource utilisation for chronic kidney disease and other major non-communicable chronic diseases in China: a cross-sectional study

Yang

Long

Shi³

et al. 2022

BMJ Open

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…After stage 3, the above symptoms become more obvious, with increased risks of hypertension, heart failure, bone disease, anemia, gastrointestinal symptoms, and a progress to end-stage kidney failure without proper intervention and treatment. [5,6] At present, the main principles for CKD are treating original diseases, low-protein diet, essential amino acids intake, and management of complications. Although it could slow down the damage to kidney function, long-term low-protein diet can aggravate malnutrition in patients.…”

Section: Introductionmentioning

confidence: 99%

“…Initially, the symptoms of CKD are insidious and then presented with fatigue, swelling legs, dizziness, and loss of appetite gradually. After stage 3, the above symptoms become more obvious, with increased risks of hypertension, heart failure, bone disease, anemia, gastrointestinal symptoms, and a progress to end-stage kidney failure without proper intervention and treatment [5,6] …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bailing Capsule combined with α-ketoacid tablets for stage 3 chronic kidney disease

Wang²,

Yang³

et al. 2021

Medicine

View full text Add to dashboard Cite

Background: Chronic kidney disease (CKD) is a progressive and irreversible loss of kidney function. After stage 3, there will be increased risks of hypertension, heart failure, bone disease, anemia, gastrointestinal symptoms, and progression to end-stage kidney failure without proper intervention and treatment. Compound α-ketoacid tablets (KA) administration plays an important role in clinical CKD adjunctive therapy for patients with restricted protein intake. Bailing Capsule (BC), a commonly used Chinese patent medicine for renal diseases, could regulate human immune function, repair renal tubular epithelial cells, prevent renal tubular atrophy, and reduce kidney damage to improve renal function. In this study, we try to conduct a double-blinded, randomized, controlled trial to observe the efficacy and safety of BC combined with KA in treating patients with stage 3 CKD. Methods: This is a double-blinded, randomized, controlled trial. Patients will be randomly divided into treatment group (BC and KT) and control group (BC-simulation and KT) in a 1:1 ratio according to random number table. The treatment course will be 8 weeks, and the changes of subjective symptoms, patient global assessment (PGA) scale, serum creatinine, cystatin C, and estimated glomerular filtration rate, all related adverse events, vital sign measurements, and physical examinations will be recorded. SPSS 21.0 will be used for data analysis. Conclusions: The results will show whether BC combined with KA could alleviate the symptoms of fatigue, anorexia, halitosis, nausea, itching, and edema, improve kidney function in patients with CKD at stage 3. Trial registration: OSF Registration number: DOI 10.17605/OSF.IO/24AJ7.

show abstract

Value-Based Care and Kidney Disease: Emergence and Future Opportunities

Tummalapalli

Mendu

2022

Advances in Chronic Kidney Disease

View full text Add to dashboard Cite

Association of Chronic Condition Special Needs Plan With Hospitalization and Mortality Among Patients With End-Stage Kidney Disease

Cited by 4 publications

References 7 publications

Healthcare resource utilisation for chronic kidney disease and other major non-communicable chronic diseases in China: a cross-sectional study

Healthcare resource utilisation for chronic kidney disease and other major non-communicable chronic diseases in China: a cross-sectional study

Bailing Capsule combined with α-ketoacid tablets for stage 3 chronic kidney disease

Value-Based Care and Kidney Disease: Emergence and Future Opportunities

Contact Info

Product

Resources

About